PRLD

Prelude Therapeutics Inc

• Simply Wall St·05/16 14:20

  Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

• TipRanks·05/15 09:13

  Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

• Simply Wall St·05/13 22:50

  Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives

• TipRanks·05/12 12:04

  Prelude Therapeutics Launches Phase 1 Trial and Extends Runway

• Seeking Alpha·05/12 11:34

  Prelude Therapeutics GAAP EPS of -$0.13 beats by $0.12, revenue of $4.58M

• Reuters·05/12 11:13

  Prelude Therapeutics Q1 net loss narrows as expenses fall

• Dow Jones·05/12 11:02

  *Prelude Therapeutics 1Q Rev $4.58M >PRLD

• Dow Jones·05/12 11:02

  *Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD

• Reuters·05/12 11:01

  PRELUDE THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

• Dow Jones·05/12 11:01

  *Prelude Therapeutics 1Q Loss $10.4M >PRLD

• Dow Jones·05/04 14:08

  Prelude Therapeutics Initiated at Buy by D. Boral Capital

• Dow Jones·05/04 14:08

  Prelude Therapeutics Price Target Announced at $9.00/Share by D. Boral Capital

• Benzinga·05/04 13:58

  D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

• TipRanks·05/04 11:35

  Prelude Therapeutics initiated with a Buy at D. Boral Capital

• TipRanks·05/02 16:30

  Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers